Barclays PLC Increases Stake in Xencor, Inc. (NASDAQ:XNCR)

Barclays PLC increased its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 112.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 330,745 shares of the biopharmaceutical company's stock after purchasing an additional 175,177 shares during the period. Barclays PLC owned approximately 0.47% of Xencor worth $7,600,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Finepoint Capital LP bought a new stake in Xencor during the 4th quarter valued at $15,167,000. Vanguard Group Inc. lifted its position in Xencor by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after purchasing an additional 418,040 shares during the period. Loomis Sayles & Co. L P grew its position in Xencor by 21.3% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock valued at $25,102,000 after buying an additional 192,080 shares during the period. Geode Capital Management LLC increased its position in Xencor by 12.3% in the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock worth $37,578,000 after buying an additional 179,526 shares in the last quarter. Finally, Norges Bank bought a new stake in Xencor during the 4th quarter worth approximately $3,397,000.

Xencor Price Performance

Shares of Xencor stock traded up $0.03 on Tuesday, hitting $10.63. The company's stock had a trading volume of 45,435 shares, compared to its average volume of 625,467. The company has a market capitalization of $756.42 million, a price-to-earnings ratio of -3.32 and a beta of 0.90. The firm has a fifty day moving average price of $11.66 and a 200-day moving average price of $18.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, sell-side analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on XNCR shares. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. William Blair initiated coverage on Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Finally, StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Xencor currently has an average rating of "Moderate Buy" and an average target price of $33.86.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.